- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01453777
Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Diffuse Lesions in the Brain
July 19, 2017 updated by: Ageless Regenerative Institute
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Via Catheter Into the Internal Carotid Artery and Intravenously in Patients With Diffuse Lesions in the Brain
The intent of this clinical study is to answer the questions:
- Is the proposed treatment safe
- Is treatment effective in improving the disease pathology of patients with diffuse brain lesions and clinical outcomes.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
This will be an open-label, non-randomized multi-center patient sponsored study of Adipose-Derived Stromal Cells (ASC) implantation using a catheter delivery system.
ASCs will be derived from the patient's adipose-derived tissue.
Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells.
The cells will be delivered via catheter into the internal carotid artery and intravenously.
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Baja California
-
Tijuana, Baja California, Mexico, 22010
- Hospital Angeles
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and Females between Age 18 and 80 years.
- Patient with current diagnosis of Diffuse Brain Lesions with cognitive and/or functional impairment
- MRI not showing gross atrophy or any other pathology of brain.
- Up to date on all age and gender appropriate cancer screening per American Cancer Society
Exclusion Criteria:
- Contraindication for MRI
- General medical contraindications for minor surgery or angiography
- Females who are pregnant or nursing or females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study
- Life expectancy < 6 months due to concomitant illnesses.
- Exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study.
- Active infectious disease. Patients known to have tested positive will have an expert consulted as to patient eligibility based on the patient's infectious status
- Any illness which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
- Patients on chronic immunosuppressive transplant therapy
- Systolic blood pressure (supine) ≤90 mmHg;
- Resting heart rate > 100 bpm;
- Active clinical infection within one week of enrollment.
- Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate.
- History of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in the last five years.
- Unwilling and/or not able to give written informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in standardized Gross Motor Function Measure evaluation compared to baseline
Time Frame: 3 months
|
3 months
|
|
Number of participants with adverse events
Time Frame: up to 6 months
|
The safety of adipose-derived stem cell injection will be evaluated by assessment of the frequency and nature of adverse events occurring during the study injection and up to the 6-month period following treatment.
|
up to 6 months
|
Improved cognitive function as measured by the mini mental state exam
Time Frame: 3 months
|
3 months
|
|
Improvement in standardized Gross Motor Function Measure evaluation compared to baseline
Time Frame: 6 months
|
6 months
|
|
Improved cognitive function as measured by the mini mental state exam compared to baseline
Time Frame: 6 months
|
6 months
|
|
Reduced depressive symptoms measured by the Beck Depression Inventory compared to baseline
Time Frame: 3 months
|
3 months
|
|
Reduced depressive symptoms measured by the Beck Depression Inventory compared to baseline
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
number of brain lesions by MRI compared to baseline
Time Frame: 3 months
|
3 months
|
Improved quality of life scores compared to baseline
Time Frame: 3 months
|
3 months
|
Improved quality of life scores compared to baseline
Time Frame: 6 months
|
6 months
|
number of brain lesions by MRI compared to baseline
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2011
Primary Completion (Anticipated)
December 1, 2014
Study Completion (Anticipated)
June 1, 2015
Study Registration Dates
First Submitted
October 3, 2011
First Submitted That Met QC Criteria
October 17, 2011
First Posted (Estimate)
October 18, 2011
Study Record Updates
Last Update Posted (Actual)
July 21, 2017
Last Update Submitted That Met QC Criteria
July 19, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- ADI-ME-DL-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Lesion (General)
-
PD Dr. med. Margret Hund-GeorgiadisSwiss Tropical & Public Health Institute; Rehab BaselCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
M.D. Anderson Cancer CenterRecruitingBrain LesionUnited States
-
University Hospital of PatrasCompleted
-
Johann Wolfgang Goethe University HospitalUnknownBrain Lesion, Stereotactic BiopsyGermany
-
GuerbetCompletedHealthy Volunteers | Brain LesionBelgium
-
National Institute of Mental Health (NIMH)Completed
-
GuerbetCompletedBlood Brain Barrier Defect | CNS LesionKorea, Republic of, United States, Czechia, Italy, Belgium, Poland, Hungary, Mexico
-
National Institute of Mental Health (NIMH)RecruitingfMRI | Focal Brain Lesion | Focal LesionsUnited States
Clinical Trials on harvesting and implantation of adipose derived stem cells
-
Ageless Regenerative InstituteWithdrawnParkinson's DiseaseUnited States
-
Ageless Regenerative InstituteInstituto de Medicina RegenerativaWithdrawnIschemic Congestive Heart FailureMexico
-
Ageless Regenerative InstituteInstituto de Medicina RegenerativaWithdrawnNon-Ischemic Congestive Heart FailureMexico
-
Ageless Regenerative InstituteInstituto de Medicina RegenerativaWithdrawn
-
Ageless Regenerative InstituteInstituto de Medicina RegenerativaWithdrawn
-
Instituto de Investigación Hospital Universitario...UnknownRecto-vaginal FistulaSpain
-
University of Science Ho Chi Minh CityVan Hanh General Hospital; Nguyen Tri Phuong Hospital, Ho Chi Minh city, Viet... and other collaboratorsUnknown
-
Martha Haahr M.DOdense University HospitalUnknownDelayed Graft FunctionDenmark
-
Bioheart, Inc.WithdrawnChronic Obstructive Pulmonary DiseaseUnited States
-
Bioheart, Inc.WithdrawnDry Macular DegenerationUnited States